Trevena

Trevena CROIC

The Cash Return on Invested Capital (CROIC) of Trevena (TRVN) as of Nov 5, 2026 is -115.70 %. In the previous year, Cash Return on Invested Capital (CROIC) was -145.64 % — a change of -20.56% (higher).

CROIC

-115.70 %

YoY

-20.56%

Last updated:

Cash Return on Invested Capital (CROIC) of Trevena is 2023 -115.70 % . Cash Return on Invested Capital (CROIC) of Trevena was 2022 -145.64 % . It decreases by -20.56% higher compared to the previous year.

The Trevena CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2016
-95.10 USD
Jan 1, 2017
-119.00 USD
Jan 1, 2018
-43.35 USD
Jan 1, 2019
-54.42 USD
Jan 1, 2020
-19.15 USD
Jan 1, 2021
-70.00 USD
Jan 1, 2022
-145.64 USD
Jan 1, 2023
-115.70 USD
The Trevena CROIC history
YEARCROICYoY
-115.70 %-20.56%
-145.64 %+108.05%
-70.00 %+265.59%
-19.15 %-64.81%
-54.42 %+25.52%
-43.35 %-63.57%
-119.00 %+25.13%
-95.10 %+322.04%
-22.53 %-42.46%
-39.16 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Trevena Stock analysis

What does Trevena do? Trevena, Inc. develops and commercializes novel medicines for central nervous system disorders, focusing on OLINVO for moderate-to-severe acute pain management in hospitals and ambulatory surgery centers. The company commercializes OLINVO in the United States under its own brand, targeting healthcare providers in acute care settings. TRV250, a non-narcotic migraine treatment with potential for other CNS indications, is in Phase I development in the United Kingdom, with the company advancing its research through its ABLE product platform. Trevena leverages its ABLE platform to identify GPCR-targeted biased ligands, supporting its pipeline development without external partnerships or third-party sales. The company generates revenue through the commercialization of OLINVO in the U.S. acute care market, with healthcare facilities and providers as primary buyers. TRV250 remains in development, with no current sales, but the company anticipates future revenue once it progresses through clinical trials. Trevena’s ABLE platform serves as a foundational asset for discovering new compounds, reducing reliance on external licensing or collaborations. Its focus on G protein pathway selective modulators and biased ligands differentiates its product portfolio in CNS therapeutics. Trevena is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Trevena stock

Cash Return on Invested Capital (CROIC) of Trevena is -115.70 % in 2023.

Cash Return on Invested Capital (CROIC) of Trevena changed from -145.64 % to -115.70 %, representing a -20.56% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Trevena since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Trevena with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Trevena

All Key Metrics — Trevena